Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.
During a company webcast, Chief Executive Officer Mark Velleca said the results would be presented at the ASCO annual meeting on May 30 by Dr. Julia Rotow of the Dana-Farber Cancer Institute. Velleca described the data as showing “robust progression-free survival” in a patient population with significant unmet medical need.
